ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1560

Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis

Frank Behrens1,2, Michaela Koehm2,3, Eva C. Scharbatke4, Bianca Wittig5, Marc Schmalzing4, Holger Gnann6, H M Lorenz7, Diamant Thaci8 and Harald Burkhardt1,9, 1Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, 2Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, 3Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, 4Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, 5Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 6Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, 7University Hospital Heidelberg, Heidelberg, Germany, 8Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, 9Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ,

Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. 

Methods

We evaluated baseline characteristics of active PsA patients enrolled in a German observational multicenter study with Adalimumab (ADA). Multiple logistic regression analyses were utilized to identify risk factors for osteoporosis. Risk factors were confirmed in a validation cohort.

Results

At baseline, 6.0% (N=88) of patients in the initial PsA cohort (N=1467) had osteoporosis as indicated by medical history. Logistic regression analyses (1194 patients with adequate data for modeling) found that age, systemic glucocorticoid use and rheumatoid factor (RF) seropositivity were significantly associated with osteoporosis. As the association between RF status and osteoporosis has not been previously described in PsA, we evaluated a second cohort of PsA patients (validation cohort; N = 1762) to determine whether this association could be verified. As in the initial cohort, positive RF status was associated with a >2-fold increase in the risk of osteoporosis in patients with PsA in the same range as use of glucocorticoids. The rate of osteoporosis was 5.4% (168/3102) in the total cohort and 12.1% (35/290) in RF-positive patients. Analysis of typical PsA-features like confirmed nail involvement, enthesitis and dactylitis and active psoriasis suggests that it is unlikely that the RF-positive PsA patients were misdiagnosed RA-cases. The full set of predictors of osteoporosis of the full cohort (2956 patients with adequate data) is shown in Table 1. Negative predictors were male gender and higher functional (FFbH) scores.

Conclusion

RF seropositivity is an independent risk factor for osteoporosis in active PsA patients. Other variables that increase the risk of osteoporosis are steroid use, older age, longer disease duration, recent hospitalization, female gender, and worse functional status.

Disclosure:

F. Behrens,

AbbVie,

5,

Chugai,

8,

Chugai,

5,

Roche Pharmaceuticals,

5,

Janssen Pharmaceutica Product, L.P.,

5;

M. Koehm,

AbbVie,

2,

Pfizer Inc,

2;

E. C. Scharbatke,

AbbVie,

5,

Chugai,

5,

Roche Pharmaceuticals,

5;

B. Wittig,

AbbVie,

3;

M. Schmalzing,

AbbVie,

5,

Roche Pharmaceuticals,

5,

Actelion Pharmaceuticals US,

5,

BMS,

5,

Chugai,

5,

UCB,

5,

Pfizer Inc,

5;

H. Gnann,

AbbVie,

5;

H. M. Lorenz,

AbbVie,

5,

Roche Pharmaceuticals,

5,

Actelion Pharmaceuticals US,

5,

Pfizer Inc,

5,

BMS,

5,

Chugai,

5,

UCB,

5;

D. Thaci,

Abbvie,

5,

Lilly,

5,

Amgen,

5,

Pfizer Inc,

5,

MSD,

5,

Novartis Pharmaceutical Corporation,

5,

Biogen Idec,

5,

Leo Pharma,

5;

H. Burkhardt,

Pfizer Inc,

2,

Pfizer Inc,

5,

AbbVie,

5,

UCB,

5,

BMS,

5,

Chugai,

5.

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-factor-status-is-a-predictor-of-osteoporosis-in-patients-with-psoriatic-arthritis/